Cargando…

Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites

Sustained-release olmesartan tablets (OLM) were prepared by the simple, direct compression of composites of anionic sulfobutyl ether-β-cyclodextrin (SBE-β-CD) and cationic spray-dried chitosan (SD-CS), and were evaluated for use as a sustained release preparation for the treatment of hypertension. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Anraku, Makoto, Tabuchi, Ryo, Goto, Miwa, Iohara, Daisuke, Mizukai, Yasuyuki, Maezaki, Yuji, Michihara, Akihiro, Kadowaki, Daisuke, Otagiri, Masaki, Hirayama, Fumitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409563/
https://www.ncbi.nlm.nih.gov/pubmed/30781383
http://dx.doi.org/10.3390/pharmaceutics11020082
_version_ 1783402002770821120
author Anraku, Makoto
Tabuchi, Ryo
Goto, Miwa
Iohara, Daisuke
Mizukai, Yasuyuki
Maezaki, Yuji
Michihara, Akihiro
Kadowaki, Daisuke
Otagiri, Masaki
Hirayama, Fumitoshi
author_facet Anraku, Makoto
Tabuchi, Ryo
Goto, Miwa
Iohara, Daisuke
Mizukai, Yasuyuki
Maezaki, Yuji
Michihara, Akihiro
Kadowaki, Daisuke
Otagiri, Masaki
Hirayama, Fumitoshi
author_sort Anraku, Makoto
collection PubMed
description Sustained-release olmesartan tablets (OLM) were prepared by the simple, direct compression of composites of anionic sulfobutyl ether-β-cyclodextrin (SBE-β-CD) and cationic spray-dried chitosan (SD-CS), and were evaluated for use as a sustained release preparation for the treatment of hypertension. An investigation of the interaction between OLM and SBE-β-CD by the solubility method indicated that the phase diagram of the OLM/SBE-β-CD system was the A(L) type, indicating the formation of a 1:1 inclusion complex. The release of OLM from tablets composed of the SD-CS/SBE-β-CD composite was slow in media at both pH 1.2 and at 6.8. The in vitro slow release characteristics of the SD-CS/SBE-β-CD composite were reflected in the in vivo absorption of the drug after normal rats were given an oral administration of the preparation. Furthermore, the SD-CS/SBE-β-CD composite continuously increased the antihypertensive effect of OLM in hypertensive rats, compared with that of the drug itself. These results suggest that a simple mixing of SD-CS and SBE-β-CD can be potentially useful for the controlled release of a drug for the continuous treatments of hypertension.
format Online
Article
Text
id pubmed-6409563
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64095632019-03-29 Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites Anraku, Makoto Tabuchi, Ryo Goto, Miwa Iohara, Daisuke Mizukai, Yasuyuki Maezaki, Yuji Michihara, Akihiro Kadowaki, Daisuke Otagiri, Masaki Hirayama, Fumitoshi Pharmaceutics Article Sustained-release olmesartan tablets (OLM) were prepared by the simple, direct compression of composites of anionic sulfobutyl ether-β-cyclodextrin (SBE-β-CD) and cationic spray-dried chitosan (SD-CS), and were evaluated for use as a sustained release preparation for the treatment of hypertension. An investigation of the interaction between OLM and SBE-β-CD by the solubility method indicated that the phase diagram of the OLM/SBE-β-CD system was the A(L) type, indicating the formation of a 1:1 inclusion complex. The release of OLM from tablets composed of the SD-CS/SBE-β-CD composite was slow in media at both pH 1.2 and at 6.8. The in vitro slow release characteristics of the SD-CS/SBE-β-CD composite were reflected in the in vivo absorption of the drug after normal rats were given an oral administration of the preparation. Furthermore, the SD-CS/SBE-β-CD composite continuously increased the antihypertensive effect of OLM in hypertensive rats, compared with that of the drug itself. These results suggest that a simple mixing of SD-CS and SBE-β-CD can be potentially useful for the controlled release of a drug for the continuous treatments of hypertension. MDPI 2019-02-15 /pmc/articles/PMC6409563/ /pubmed/30781383 http://dx.doi.org/10.3390/pharmaceutics11020082 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Anraku, Makoto
Tabuchi, Ryo
Goto, Miwa
Iohara, Daisuke
Mizukai, Yasuyuki
Maezaki, Yuji
Michihara, Akihiro
Kadowaki, Daisuke
Otagiri, Masaki
Hirayama, Fumitoshi
Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites
title Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites
title_full Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites
title_fullStr Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites
title_full_unstemmed Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites
title_short Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites
title_sort design and evaluation of an extended-release olmesartan tablet using chitosan/cyclodextrin composites
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409563/
https://www.ncbi.nlm.nih.gov/pubmed/30781383
http://dx.doi.org/10.3390/pharmaceutics11020082
work_keys_str_mv AT anrakumakoto designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites
AT tabuchiryo designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites
AT gotomiwa designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites
AT ioharadaisuke designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites
AT mizukaiyasuyuki designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites
AT maezakiyuji designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites
AT michiharaakihiro designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites
AT kadowakidaisuke designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites
AT otagirimasaki designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites
AT hirayamafumitoshi designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites